DOPF

2,5-Dimethoxy-4-(3-fluoropropyl)amphetamine (DOPF) is a designer drug from the amphetamine and DOx families. It was first synthesised by Alexander Shulgin and David Nichols in 1989 but was never published at the time, and was finally disclosed in Daniel Trachsel's review of the field in 2013. It has a binding affinity (K_i) of 9 nM at the serotonin receptor 5-HT_2A but is not known to have been tested in humans.^[1]

DOPF

Clinical data
Other names	2,5-Dimethoxy-4-(3-fluoropropyl)amphetamine
Identifiers
IUPAC name 2-[4-(3-fluoropropyl)-2,5-dimethoxyphenyl]ethanamine
PubChem CID	163192484
CompTox Dashboard (EPA)	DTXSID001337046
Chemical and physical data
Formula	C14H22FNO2
Molar mass	255.333 g·mol−1
3D model (JSmol)	Interactive image
SMILES COc1cc(CCCF)c(cc1CC(C)N)OC
InChI InChI=1S/C14H22FNO2/c1-10(16)7-12-9-13(17-2)11(5-4-6-15)8-14(12)18-3/h8-10H,4-7,16H2,1-3H3 Key:UIHSFMYQJAKMHD-UHFFFAOYSA-N

See also

• DOBU
• DOEF
• DOPR
• DOTFM
• 2C-TFE
• 2C-T-21
• 2C-T-28